AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer

AbbVie Announces Availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the Treatment of Platinum-Resistant Ovarian Cancer PR Newswire

SINGAPORE, July 29, 2026 * ELAHERE is the first and only antibody-drug conjugate (ADC) therapy approved specifically for patients with folate receptor alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian cancer, fallopian tube or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. * As monotherapy, ELAHERE demonstrated a 37% reduction in the risk of disease progression or death versus prior standard chemotherapy, more than double the objective response rate and showed a meaningful improvement in overall survival([1]) * The NCCN Guidelines recommend FRα testing for patients with ovarian cancer, and suggest ELAHERE for those who are FRα-positive.([2]) SINGAPORE, July 29, 2026 /PRNewswire/ -- AbbVie today announced the availability of ELAHERE® (mirvetuximab soravtansine) in Singapore for the treatment of platinum-resistant high grade serous epithelial ovarian cancer, fallopian tube or primary peritoneal cancer.